<DOC>
	<DOC>NCT00844285</DOC>
	<brief_summary>The purpose of this study is to monitor safety outcomes of patients who have taken Cimzia® as compared to a non- Cimzia® control population. The SECURE Registry's target enrollment is 4000 patients and it's objective is to monitor patients for approximately 10 years.</brief_summary>
	<brief_title>SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry</brief_title>
	<detailed_description>Physicians are expected to manage patients as they would under normal practice conditions; patients will receive and use their medications according to their normal course of medical treatment.</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Patient must have medically documented Crohn's disease The decision to prescribe Cimzia or other medications has been made by the physician independent of inclusion in this study Patient (or his/her legally acceptable representative) is able to provide written informed consent to permit collection of data Patients participating in randomized, blinded clinical trials for CD or other conditions are not eligible for inclusion into the SECURE registry. Involvement in other registries, where patients follow routine clinical practice, is permitted, however For the Cimzia cohort: Patient is receiving treatment with Cimzia for the first time. Patient must receive Cimzia treatment within 2 months of enrollment into the registry Patient is currently receiving treatment with Cimzia for ≤12 months. Patient must also receive a Cimzia dose within 2 months following enrollment into the registry For the comparison cohort: Patient is switching CD treatment or beginning CD treatment for the first time. Previous Cimzia treatment is prohibited in the comparator group. Patient must receive new CD treatment within 2 months of enrollment into the registry. Patient is currently receiving antiTNF treatment for ≤12 months. Patient must receive antiTNF treatment within 2 months following enrollment into the registry. Patient is currently receiving immunosuppressant therapy for ≤12 months. Patient must receive immunosuppressant therapy within 2 months following enrollment into the registry. Patient is currently receiving systemic steroid therapy for ≤12 months. Patient must receive systemic steroid therapy within 2 months following enrollment into registry See inclusion criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Certolizumab Pegol, Cimzia ®</keyword>
	<keyword>Crohn's Disease</keyword>
</DOC>